Potential of the quadrivalent human papillomavirus vaccine in the prevention and treatment of cervical cancer

Bibliography

• Koutsky LA, Ault KA, Wheeler CM, et al. A controlled trial of a human papillomavirus type 16 vaccine. N Engl J Med 2002;347(21):1645-51
   PubMed Web of Science ®Google Scholar
• Crum CP. The beginning of the end for cervical cancer? N Engl J Med 2002;347(21):1703-5
   PubMed Web of Science ®Google Scholar
• Ali H, Donovan B, Wand H, et al. Genital warts in young Australians five years into national human papillomavirus vaccination programme: national surveillance data. BMJ 2013;346:f2032
   PubMed Web of Science ®Google Scholar
• Brotherton JM, Fridman M, May CL, et al. Early effect of the HPV vaccination programme on cervical abnormalities in Victoria, Australia: an ecological study. Lancet 2011;377(9783):2085-92
   PubMed Web of Science ®Google Scholar
• Gertig DM, Brotherton JM, Saville M. Measuring human papillomavirus (HPV) vaccination coverage and the role of the National HPV Vaccination Program Register, Australia. Sex Health 2011;8(2):171-8
   PubMed Web of Science ®Google Scholar
• Garland SM, Skinner SR, Brotherton JM. Adolescent and young adult HPV vaccination in Australia: achievements and challenges. Prev Med 2011;53(Suppl 1):S29-35
   PubMed Web of Science ®Google Scholar
• Garland SM, Hernandez-Avila M, Wheeler CM, et al. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med 2007;356(19):1928-43
   PubMed Web of Science ®Google Scholar
• The Future II Study Group. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. NEJM 2007;356(19):1915-27
   PubMed Web of Science ®Google Scholar
• Kjaer SK, Sigurdsson K, Iversen OE, et al. A pooled analysis of continued prophylactic efficacy of quadrivalent human papillomavirus (types 6/11/16/18) vaccine against high-grade cervical and external genital lesions. Cancer Prev Res (Phila) 2009;2(10):868-78
   PubMed Web of Science ®Google Scholar
• Giuliano AR, Palefsky JM, Goldstone S, et al. Efficacy of quadrivalent HPV vaccine against HPV infection and disease in males. N Engl J Med 2011;364(5):401-11
   PubMed Web of Science ®Google Scholar
• Palefsky JM, Giuliano AR, Goldstone S, et al. HPV vaccine against anal HPV infection and anal intraepithelial neoplasia. N Engl J Med 2011;365(17):1576-85
   PubMed Web of Science ®Google Scholar
• Ferlay J, Shin HR, Bray F, et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010;127(12):2893-917
   PubMed Web of Science ®Google Scholar
• Block SL, Nolan T, Sattler C, et al. Comparison of the immunogenicity and reactogenicity of a prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in male and female adolescents and young adult women. Pediatrics 2006;118(5):2135-45
   PubMed Web of Science ®Google Scholar
• Olsson S, Villa L, Costa R, et al. Induction of immune memory following administration of a prophylactic quadrivalent human papillomavirus (HPV) types 6/11/16/18 L1 virus-like particle (VLP) vaccine. Vaccine 2007;25(26):4931-9
   PubMed Web of Science ®Google Scholar
• Roberts JN, Buck CB, Thompson CD, et al. Genital transmission of HPV in a mouse model is potentiated by nonoxynol-9 and inhibited by carrageenan. Nat Med 2007;13(7):857-61
   PubMed Web of Science ®Google Scholar
• Schiller JT, Lowy DR. Immunogenicity testing in human papillomavirus virus-like-particle vaccine trials. J Infect Dis 2009;200(2):166-71
   PubMed Web of Science ®Google Scholar
• Carter JJ, Wipf GC, Madeleine MM, et al. Identification of human papillomavirus type 16 L1 surface loops required for neutralization by human sera. J Virol 2006;80(10):4664-72
   PubMed Web of Science ®Google Scholar
• Pastrana DV, Buck CB, Pang YY, et al. Reactivity of human sera in a sensitive, high-throughput pseudovirus-based papillomavirus neutralization assay for HPV16 and HPV18. Virology 2012;321(2):205-16
   Google Scholar
• Smith JF, Kowalski R, Esser MT, et al. Evolution of type-specific immunoassays to evaluate the functional immune response to Gardasil®, a vaccine for human papillomavirus types 16, 18, 6, and 11. Hum Vaccin 2008;4(2):134-42
   PubMed Web of Science ®Google Scholar
• Brown DR, Garland S. Cervical cancer vaccines. Principals Pract Oncol 2008;22(4):1-12
   Google Scholar
• Joura EA, Kjaer SK, Wheeler CM, et al. HPV antibody levels and clinical efficacy following administration of a prophylactic quadrivalent HPV vaccine. Vaccine 2008;26(52):6844-51
   PubMed Web of Science ®Google Scholar
• WHO, (World Health Organisation). Guidelines on Non Clinical Evaluation of Vaccines: WHO Technical Report Series; 2003
   Google Scholar
• CHMP (Committee for Medical Products for Human Use). Guideline on Clinical Evaluation of New Vaccines. Report; 2006
   Google Scholar
• Lowy DR, Frazer IH. Prophylactic human papillomavirus vaccines. JNCI Monogr 2003;2003(31):111-16
   Google Scholar
• Pagliusi SR, Teresa AM. Efficacy and other milestones for human papillomavirus vaccine introduction. Vaccine 2004;23(5):569-78
   PubMed Web of Science ®Google Scholar
• Dillner J, Kjaer SK, Wheeler CM, et al. Four year efficacy of prophylactic human papillomavirus quadrivalent vaccine against low grade cervical, vulvar, and vaginal intraepithelial neoplasia and anogenital warts: randomised controlled trial. BMJ 2010;341:c3493
   PubMed Web of Science ®Google Scholar
• Muñoz N, Kjaer SK, Sigurdsson K, et al. Impact of human papillomavirus (HPV)-6/11/16/18 vaccine on all HPV-associated genital diseases in young women. J Nat Cancer Inst 2010;102(5):325-39
   PubMed Web of Science ®Google Scholar
• Muñoz N, Manalastas RJr, Pitisuttithum P, et al. Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine in women aged 24–45 years: a randomised, double-blind trial. Lancet 2009;373(9679):1949-57
   PubMed Web of Science ®Google Scholar
• Castellsagué X, Muñoz N, Pitisuttithum P, et al. End-of-study safety, immunogenicity, and efficacy of quadrivalent HPV (types 6, 11, 16, 18) recombinant vaccine in adult women 24 – 45 years of age. Br J Cancer 2011;105(1):28-37
   PubMed Web of Science ®Google Scholar
• Tabrizi SN, Brotherton JML, Kaldor JM, et al. Fall in human papillomavirus prevalence following a national vaccination program. J Infect Dis 2012;206(11):1645-51
   PubMed Web of Science ®Google Scholar
• Tabrizi SN, Brotherton JML, Kaldor JM, et al. Human papillomavirus prevalence following a national vaccination program [abstract SS22-1]. EUROGIN; Florence Italy; 2013
   Google Scholar
• Ali H, Guy RJ, Wand H, et al. Decline in in-patient treatments of genital warts among young Australians following the national HPV vaccination program. BMC Infect Dis 2013;13(1):1-6
   PubMedGoogle Scholar
• Gertig DM, Brotherton JM, Budd AC, et al. Impact of a population-based HPV vaccination program on cervical abnormalities: a data linkage study. BMC Med 2013;11(1):227
   PubMedGoogle Scholar
• Australian Government. HPV school vaccination program. Available from: http://hpv.health.gov.au
   Google Scholar
• HPV vaccine uptake 2011 to 2012: provisional data for 1 September 2011 to 31 August 2012. Public Health England. Available from: https://www.gov.uk/government/organisations/public-health-england Published 23 September 2013
   Google Scholar
• Shearer BD. HPV Vaccination: understanding the impact of HPV disease. Purple Paper 2011;34:18
   Google Scholar
• Centers for Disease Control and Prevention (CDC). Human papillomavirus vaccination coverage among adolescent girls, 2007-2012, and post licensure vaccine safety monitoring, 2006-2013 - United States. MMWR Morb Mortal Wkly Rep 2013;62(29):591-5
   PubMed Web of Science ®Google Scholar
• Statens Serum Institute. HPV Vaccination - Coverage 2012. EPI NEWS - Statens Serum Institut 2013; 20
   Google Scholar
• Bauer HM, Wright G, Chow J. Evidence of human papillomavirus vaccine effectiveness in reducing genital warts: an analysis of California public family planning administrative claims data, 2007–2010. Am J Public Health 2012;102(5):833-5
   PubMed Web of Science ®Google Scholar
• Markowitz LE, Hariri S, Unger ER, et al. Post-licensure monitoring of HPV vaccine in the United States. Vaccine 2010;28(30):4731-7
   PubMed Web of Science ®Google Scholar
• Garland SM, Ault KA, Gall SA, et al. Pregnancy and infant outcomes in the clinical trials of a human papillomavirus type 6/11/16/18 vaccine: a combined analysis of five randomized controlled trials. Obstet Gynecol 2009;114(6):1179-88
   PubMed Web of Science ®Google Scholar
• Agorastos T, Chatzigeorgiou K, Brotherton JM, et al. Safety of human papillomavirus (HPV) vaccines: a review of the international experience so far. Vaccine 2009;27(52):7270-81
   PubMed Web of Science ®Google Scholar
• Dana A, Buchanan KM, Goss MA, et al. Pregnancy outcomes from the pregnancy registry of a human papillomavirus type 6/11/16/18 vaccine. Obstet Gynecol 2009;114(6):1170-8
   PubMed Web of Science ®Google Scholar
• Slade BA, Leidel L, Vellozzi C, et al. Postlicensure safety surveillance for quadrivalent human papillomavirus recombinant vaccine. JAMA 2009;302(7):750-7
   PubMed Web of Science ®Google Scholar
• Buttery JP, Madin S, Crawford NW, et al. Mass psychogenic response to human papillomavirus vaccination. Med J Aust 2008;189(5):261-2
   PubMed Web of Science ®Google Scholar
• Clements CJ. Mass psychogenic illness after vaccination. Drug Saf 2003;26(9):599-604
   PubMed Web of Science ®Google Scholar
• Crawford NW, Clothier HJ, Elia S, et al. Syncope and seizures following human papillomavirus vaccination: a retrospective case series. Med J Aust 2011;194(1):16
   PubMed Web of Science ®Google Scholar
• Barbaro B, Brotherton JM, Gertig DM. Human papillomavirus vaccination and cervical cancer screening by socioeconomic status, Victoria. Med J Aust 2012;196(7):445
   PubMed Web of Science ®Google Scholar
• Luxembourg A. An overview of the 9-valent HPV L1 virus-like particle vaccine clinical development program [abstract SS8-3]. EUROGIN; 3 – 6 November 2013; Florence Italy
   Google Scholar
• Joura E. Efficacy and immunogenicity of a novel 9-valent HPV L1 virus-like particle vaccine in 16 to 26 -year-old women [abstract SS 8-4]. EUROGIN; 3 – 6 November 2013; Florence, Italy
   Google Scholar
• Schiller JT, Castellsagué X, Garland SM. A review of clinical trials of human papillomavirus prophylactic vaccines. Vaccine 2012;30(Suppl 5):F123-F38
   PubMed Web of Science ®Google Scholar